OTC Watch

All stocks / EMMA

Emmaus Life Sciences, Inc. EMMA

Emmaus Life Sciences (EMMA): convertible notes mentioned in an 8-K in December 2025, a late 10-Q notice in November 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Late filingEstimated floatCostly financing OTCQBCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
EMMAUS LIFE SCIENCES INC NEW
Market tier
OTCQB
Trading status
Active
Last trade
Nov 13
Website
ir.emmausmedical.com/
Source: Stockwatch, 2026-11-17

News headlines

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
2026-08-31 09:30 · News Release
Emmaus Life Sciences Reports Quarterly Financial Results
2026-08-14 16:11 · News Release
Emmaus Life Sciences Reports Annual Financial Results
2026-03-30 22:00 · News Release
Emmaus Life Sciences Announces Strategic Transaction
2025-12-30 16:30 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$12,453,000
Net loss
($7,492,000)
What it means

It spends more than it earns

Under strain

Customers paid it $12.5 million in the year. It lost $7.5 million. For every $1 that came in, about $1.60 went out.

The report says
Cash and cash equivalents
$2,127,000
Net cash used in operating activities
($11,000)
What it means

It has cash for a while

Steady

It had $2.1 million in the bank and used about $917 a month. At that pace the money lasts about 2320 months unless it borrows or sells more shares.

The report says
Total assets
$21,436,000
Total liabilities
$85,044,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $21.4 million. Its debts and unpaid bills add up to $85 million. That is about $3.97 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Late filing2026-11-16

Filed NT 10-Q on 2026-11-16: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Estimated float2026-08-11

Estimated float about 69,498,096 shares as of 2026-08-11: 70,188,263 outstanding minus 690,167 held by 1 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2025-12-22

8-K filed 2025-12-22 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-09-30
63.9M
2025-11-11
63.9M
2025-12-31
70.2M
2026-03-25
70.2M
2026-03-31
70.2M
2026-05-11
70.2M
2026-06-30
70.2M
2026-08-11
70.2M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 NT 10-QNOTIFICATION OF LATE FILING
2026-09-02 44
2026-08-14 10-Q10-Q
2026-08-14 8-KCURRENT REPORT
2026-05-15 10-Q10-Q
2026-05-15 8-KCURRENT REPORT
2026-04-21 3
2026-04-17 8-KCURRENT REPORT
2026-04-14 8-KCURRENT REPORT
2026-03-31 10-K10-K
2026-03-31 8-KCURRENT REPORT
2026-03-04 8-KCURRENT REPORT

Common questions about EMMA

Does EMMA file reports with the SEC?

Yes. Emmaus Life Sciences files with the SEC under company number 0000822370. The most recent filing we hold is a NT 10-Q dated 2026-11-16.

Source record

How many EMMA shares are outstanding?

70,188,263 shares as of 2026-08-11, as reported to the SEC.

Source record

Has EMMA filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-Q on 2026-11-16. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs Emmaus Life Sciences?

Officers named in its insider filings: Willis C Lee (CEO).

Source record

Is Emmaus Life Sciences making money?

Customers paid it $12.5 million in the year. It lost $7.5 million. For every $1 that came in, about $1.60 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record